{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:46:52Z","timestamp":1791859612679,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Human glioma is a devastating primary brain tumor with a dismal prognosis, necessitating the identification of novel therapeutic targets. The small nuclear ribonucleoprotein C (SNRPC), a core spliceosome component, is implicated in cancer, but its role in glioma remains unexplored. This study aimed to delineate the expression, function, and underlying mechanisms of SNRPC in human glioma. The bioinformatic analysis revealed that\n                    <jats:italic>SNRPC<\/jats:italic>\n                    is significantly upregulated in glioma tissues, with expression levels correlating strongly with higher tumor grade, aggressive molecular subtypes (IDH wild-type, 1p\/19q non-codeleted), and poor patient prognosis, establishing it as a robust independent biomarker. Single-cell analysis pinpointed\n                    <jats:italic>SNRPC<\/jats:italic>\n                    enrichment in malignant glioma cells, and co-expression studies linked it to mitochondrial metabolism and oxidative phosphorylation. SNRPC expression is also upregulated in locally-resected glioma tissues and various glioma cell types. Functionally, silencing (by targeted shRNA) or knocking out (via CRISPR\/Cas9 method) of SNRPC profoundly attenuated glioma cell proliferation, migration, and invasion, while inducing G1-S arrest and apoptosis. These effects were specifically observed in malignant glioma cells, sparing normal astrocytes. Mechanistically, loss of SNRPC led to severe mitochondrial dysfunction, characterized by impaired mitochondrial respiration, ATP depletion, membrane depolarization, and excessive ROS (reactive oxygen species) production. Conversely, SNRPC overexpression enhanced mitochondrial bioenergetics and promoted malignant phenotypes. SNRPC promoted glioma malignancy by regulating the expression of a key oncogene tumor necrosis factor alpha-induced protein 2 (TNFAIP2), which acts as a key downstream effector to drive increased cell proliferation and migration. Critically, SNRPC knockdown suppressed subcutaneous glioma xenograft growth and disrupted mitochondrial bioenergetics. Its knockout also impeded the intracranial glioma growth in an orthotopic mouse model. Our findings establish SNRPC as a pivotal driver of glioma malignancy by sustaining mitochondrial hyperfunction and TNFAIP2 expression essential for tumor cell proliferation.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09065-6","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:05:57Z","timestamp":1784300757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The spliceosome component SNRPC promotes glioma progression by sustaining mitochondrial function and TNFAIP2 signaling"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-5337","authenticated-orcid":false,"given":"Peng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0349-0380","authenticated-orcid":false,"given":"Ya","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"9065_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, et al. Glioma. Nat Rev Dis Primers. 2024;10:33.","journal-title":"Nat Rev Dis Primers"},{"key":"9065_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.17","volume":"1","author":"M Weller","year":"2015","unstructured":"Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017.","journal-title":"Nat Rev Dis Primers"},{"key":"9065_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrneurol.2015.242","volume":"12","author":"PY Wen","year":"2016","unstructured":"Wen PY, Reardon DA. Neuro-oncology in 2015: progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016;12:69\u201370.","journal-title":"Nat Rev Neurol"},{"key":"9065_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrneurol.2013.268","volume":"10","author":"M Weller","year":"2014","unstructured":"Weller M, Wick W. Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol. 2014;10:68\u201370.","journal-title":"Nat Rev Neurol"},{"key":"9065_CR5","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"9065_CR6","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"9065_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"9065_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrn3060","volume":"12","author":"M Westphal","year":"2011","unstructured":"Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci. 2011;12:495\u2013508.","journal-title":"Nat Rev Neurosci"},{"key":"9065_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrclinonc.2014.223","volume":"12","author":"DA Reardon","year":"2015","unstructured":"Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015;12:69\u201370.","journal-title":"Nat Rev Clin Oncol"},{"key":"9065_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","volume":"15","author":"AM Molinaro","year":"2019","unstructured":"Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15:405\u201317.","journal-title":"Nat Rev Neurol"},{"key":"9065_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-211-78741-0_1","volume":"34","author":"F Lefranc","year":"2009","unstructured":"Lefranc F, Rynkowski M, DeWitte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3\u201335.","journal-title":"Adv Tech Stand Neurosurg"},{"key":"9065_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00401-009-0614-0","volume":"119","author":"AC Navis","year":"2010","unstructured":"Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ. Protein tyrosine phosphatases in glioma biology. Acta Neuropathol. 2010;119:157\u201375.","journal-title":"Acta Neuropathol"},{"key":"9065_CR13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","volume":"122","author":"S Han","year":"2020","unstructured":"Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580\u20139.","journal-title":"Br J Cancer"},{"key":"9065_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01513-z","volume":"21","author":"K Yang","year":"2022","unstructured":"Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21:39.","journal-title":"Mol Cancer"},{"key":"9065_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.abf1870","volume":"371","author":"S Zhang","year":"2021","unstructured":"Zhang S, Aibara S, Vos SM, Agafonov DE, Luhrmann R, Cramer P. Structure of a transcribing RNA polymerase II-U1 snRNP complex. Science. 2021;371:305\u20139.","journal-title":"Science"},{"key":"9065_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/wrna.1257","volume":"6","author":"J Guiro","year":"2015","unstructured":"Guiro J, O\u2019Reilly D. Insights into the U1 small nuclear ribonucleoprotein complex superfamily. Wiley Interdiscip Rev RNA. 2015;6:79\u201392.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"9065_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/348515a0","volume":"348","author":"K Nagai","year":"1990","unstructured":"Nagai K, Oubridge C, Jessen TH, Li J, Evans PR. Crystal structure of the RNA-binding domain of the U1 small nuclear ribonucleoprotein A. Nature. 1990;348:515\u201320.","journal-title":"Nature"},{"key":"9065_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12957-021-02354-8","volume":"19","author":"J Cai","year":"2021","unstructured":"Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol. 2021;19:241.","journal-title":"World J Surg Oncol"},{"key":"9065_CR19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/2211-5463.13175","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Qiu J, Zuo D, Yuan Y, Qiu Y, Qiao L, et al. SNRPC promotes hepatocellular carcinoma cell motility by inducing epithelial-mesenchymal transition. FEBS Open Bio. 2021;11:1757\u201370.","journal-title":"FEBS Open Bio"},{"key":"9065_CR20","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-22-0536","volume":"83","author":"XX Lu","year":"2023","unstructured":"Lu XX, Yang WX, Pei YC, Luo H, Li XG, Wang YJ, et al. An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression. Cancer Res. 2023;83:2000\u201315.","journal-title":"Cancer Res"},{"key":"9065_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cbpb.2006.09.002","volume":"146","author":"HY Wang","year":"2007","unstructured":"Wang HY, Zhou L, Gui JF. Identification of a putative oocyte-specific small nuclear ribonucleoprotein polypeptide C in gibel carp. Comp Biochem Physiol B Biochem Mol Biol. 2007;146:47\u201352.","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"9065_CR22","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1038\/s41388-018-0184-5","volume":"37","author":"YY Liu","year":"2018","unstructured":"Liu YY, Chen MB, Cheng L, Zhang ZQ, Yu ZQ, Jiang Q, et al. microRNA-200a downregulation in human glioma leads to Galphai1 over-expression, Akt activation, and cell proliferation. Oncogene. 2018;37:2890\u2013902.","journal-title":"Oncogene"},{"key":"9065_CR23","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.7150\/thno.78616","volume":"12","author":"YZ Guo","year":"2022","unstructured":"Guo YZ, Chen G, Huang M, Wang Y, Liu YY, Jiang Q, et al. TIMM44 is a potential therapeutic target of human glioma. Theranostics. 2022;12:7586\u2013602.","journal-title":"Theranostics"},{"key":"9065_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.7150\/ijbs.79355","volume":"19","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu F, Wu J, Zhang MQ, Chai JL, Cao C. G protein inhibitory alpha subunit 2 is a molecular oncotarget of human glioma. Int J Biol Sci. 2023;19:865\u201379.","journal-title":"Int J Biol Sci"},{"key":"9065_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07419-0","volume":"16","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Wu S, Cao G, Song P, Lan CG, Zhang L, et al. Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth. Cell Death Dis. 2025;16:95.","journal-title":"Cell Death Dis"},{"key":"9065_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07505-3","volume":"16","author":"J Zha","year":"2025","unstructured":"Zha J, Li J, Yin H, Shen M, Xia Y. TIMM23 overexpression drives NSCLC cell growth and survival by enhancing mitochondrial function. Cell Death Dis. 2025;16:174.","journal-title":"Cell Death Dis"},{"key":"9065_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06811-6","volume":"15","author":"F Cheng","year":"2024","unstructured":"Cheng F, Huang H, Yin S, Liu JS, Sun P. Expression and functional implications of YME1L in nasopharyngeal carcinoma. Cell Death Dis. 2024;15:423.","journal-title":"Cell Death Dis"},{"key":"9065_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102311","volume":"52","author":"M Ding","year":"2022","unstructured":"Ding M, Shi R, Cheng S, Li M, De D, Liu C, et al. Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch. Redox Biol. 2022;52:102311.","journal-title":"Redox Biol"},{"key":"9065_CR29","first-page":"223","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu F, Chen G, Zhou LN, Wang Y, Zhang ZQ, Qin X, et al. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Galphai1 expression and Akt activation. Protein Cell. 2023;14:223\u20139.","journal-title":"Protein Cell"},{"key":"9065_CR30","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.7150\/thno.61452","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu YY, Chen MB, Cheng KW, Qi LN, Zhang ZQ, et al. Neuronal-driven glioma growth requires Galphai1 and Galphai3. Theranostics. 2021;11:8535\u201349.","journal-title":"Theranostics"},{"key":"9065_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13:767.","journal-title":"Nat Commun"},{"key":"9065_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70121","volume":"30","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang H, Shang C, Hong Y. The role and applied value of mitochondria in glioma-related research. CNS Neurosci Ther. 2024;30:e70121.","journal-title":"CNS Neurosci Ther"},{"key":"9065_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12035-010-8133-5","volume":"42","author":"BB Ordys","year":"2010","unstructured":"Ordys BB, Launay S, Deighton RF, McCulloch J, Whittle IR. The role of mitochondria in glioma pathophysiology. Mol Neurobiol. 2010;42:64\u201375.","journal-title":"Mol Neurobiol"},{"key":"9065_CR34","doi-asserted-by":"crossref","unstructured":"Kong X, Lei L, Jin L, Ren C, Mi T, Wang Q, et al. SNRPC promotes chemoresistance in Wilms tumor via the NF-kappaB-CXCL17 axis regulating M2-Type TAMs infiltration and targeted nanotherapy research. J Exp Clin Cancer Res. 2026;45:97.","DOI":"10.1186\/s13046-026-03680-z"},{"key":"9065_CR35","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.2147\/IJGM.S523878","volume":"18","author":"S Wang","year":"2025","unstructured":"Wang S, Zheng Q, Chen L. Integration of bulk and single-cell RNA sequencing to identify RNA modifications-related prognostic signature in ovarian cancer. Int J Gen Med. 2025;18:2629\u201347.","journal-title":"Int J Gen Med"},{"key":"9065_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005472","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Meng F, Mao F. Single cell sequencing analysis and transcriptome analysis constructed the liquid-liquid phase separation(LLPS)-related prognostic model for endometrial cancer. Front Oncol. 2022;12:1005472.","journal-title":"Front Oncol"},{"key":"9065_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107199","volume":"204","author":"Z Fu","year":"2024","unstructured":"Fu Z, Yuan Y. TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms. Pharmacol Res. 2024;204:107199.","journal-title":"Pharmacol Res"},{"key":"9065_CR38","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1111\/jcmm.13822","volume":"22","author":"L Jia","year":"2018","unstructured":"Jia L, Shi Y, Wen Y, Li W, Feng J, Chen C. The roles of TNFAIP2 in cancers and infectious diseases. J Cell Mol Med. 2018;22:5188\u201395.","journal-title":"J Cell Mol Med"},{"key":"9065_CR39","doi-asserted-by":"crossref","unstructured":"Cencioni C, Scagnoli F, Spallotta F, Nasi S, Illi B. The \u201cSuperoncogene\u201d Myc at the crossroad between metabolism and gene expression in glioblastoma multiforme. Int J Mol Sci. 2023;24:4217.","DOI":"10.3390\/ijms24044217"},{"key":"9065_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1568009620666201016121005","volume":"21","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, Zarabi A, Hushmandi K, Moghadam ER, Hashemi F, Daneshi S, et al. C-Myc signaling pathway in treatment and prevention of brain tumors. Curr Cancer Drug Targets. 2021;21:2\u201320.","journal-title":"Curr Cancer Drug Targets"},{"key":"9065_CR41","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/jcp.27186","volume":"234","author":"L He","year":"2019","unstructured":"He L, Zhou H, Zeng Z, Yao H, Jiang W, Qu H. Wnt\/beta-catenin signaling cascade: A promising target for glioma therapy. J Cell Physiol. 2019;234:2217\u201328.","journal-title":"J Cell Physiol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09065-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09065-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09065-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:20:06Z","timestamp":1791858006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09065-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9065"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09065-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"883"}}